Feed

BTAI

BioXcel Therapeutics, Inc.

BTAI · NASDAQ

$0.07 -18.79% (-$0.02)

1M -90.28%

Market Cap $2.28M

P/E Ratio -

Div. Yield -

ROE -

Piotroski F-Score Weak

3/9

Valuation

57 /100

Fair

P/S 3.08x

P/E N/A

EV/EBITDA N/A

Growth

100 /100

Growing

Rev. growth 19.63%

EPS growth N/A

FCF growth N/A

Profitability

18 /100

Weak

Gross margin 45.28%

Net margin 9,549.86%

Op. margin 6,014.42%

Quality

58 /100

Average

ROIC 1,144.58%

ROA 246.05%

Asset turnover 0.03x

Debt

0 /100

High

Current ratio 0.21x

Int. coverage -3.11x

Debt/Equity N/A

Stability

19 /100

Unstable

Beta 0.29x

Rev. volatility 170.96%

EPS volatility 46.04%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BTAI

Online

About the company

BioXcel Therapeutics, Inc. (BTAI) is a biotechnology company that focuses on researching and developing new therapeutic approaches using artificial intelligence and data analysis. The company leverages advanced technologies and algorithms to identify and develop drugs for various diseases, including neurological and psychiatric disorders. With an innovative approach to drug development and treatment using artificial intelligence, the shares of BioXcel Therapeutics, Inc. (BTAI) may represent an intriguing investment opportunity for investors interested in biotechnology and medical research.

Sector

Healthcare

Industry

Biotechnology

CEO

Vimal D. Mehta

Employees

Headquarters

New Haven

Upcoming events

11 NOV

Earnings

Upcoming earnings report

50d

⌘ K

StockBot Live

Market situation Europe

Europe mixed as oil prices rise on Middle East risks

DAX -0.14% slips while CAC 40 +0.28% rises. Energy shares gain with oil as investors eye US-Iran talks at the UN.

Ask about this

StockBot knows 80,000+ stocks worldwide